Processa Pharmaceuticals, Inc. Debt Instrument, Unamortized Discount (Premium), Net
Processa Pharmaceuticals, Inc. (PCSA) had Debt Instrument, Unamortized Discount (Premium), Net of $967 as of 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net › Debt Instrument, Unamortized Discount (Premium), Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2017-09-25
- 2015-12-31: Debt Instrument, Unamortized Discount (Premium), Net $967.00.
- 2015-09-30: Debt Instrument, Unamortized Discount (Premium), Net $15.79K.
- 2015-06-30: Debt Instrument, Unamortized Discount (Premium), Net $30.61K.
- 2014-12-31: Debt Instrument, Unamortized Discount (Premium), Net $59.77K.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2015-12-31 | $967.00 10-K · filed 2017-09-25 |
| 2015-09-30 | $15.79K 10-Q · filed 2015-12-01 |
| 2015-06-30 | $30.61K 10-Q · filed 2015-08-19 |
| 2014-12-31 | $59.77K 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |